期刊文献+

用于肠道病毒71型灭活疫苗纯度分析的毛细管区带电泳法研究 被引量:3

Development and application of capillary zone electrophoresis for purity analysis of enterovirus type 71 inactivated vaccine
原文传递
导出
摘要 目的:建立毛细管区带电泳(capillary zone electrophoresis,CZE)方法,用于肠道病毒71型(Enterovirus 71,EV71)灭活疫苗纯度检测及分析。方法:以样品检测峰高度、分离度、信噪比为判断标准,对不同运行缓冲液、样品缓冲液、毛细管长度、上样时间等进行选择优化,确定毛细管区带电泳条件,同时采用HPLC法分离及免疫共沉淀法对各样品检测峰进行鉴定。利用建立的CZE方法对7批EV71灭活疫苗原液进行检测,采用面积归一法,计算疫苗原液纯度。结果:当运行缓冲液为pH 8.2硼酸缓冲体系、盐浓度为150 mmol·L^-1、SDS浓度为10 mmol·L^-1时,上样时间为100 s、毛细管有效长度为50 cm时,主检测峰高度最高、信噪比最优和分离度大于1.5。以含SDS 10 mmol·L^-1的150 mmol·L^-1pH 8.2硼酸盐缓冲液为运行缓冲液,5 mmol·L^-1硼酸盐缓冲液为上样缓冲液,以长50 cm、内径为50μm的无涂层石英毛细管作为色谱分离柱,对EV71灭活疫苗原液纯度进行检测,可见2个样品检测峰,经HPLC法及免疫共沉淀法鉴定,样品检测峰1为EV71病毒颗粒,迁移时间6.98 min、样品检测峰2为杂质,迁移时间8.42 min;连续进样6次,2个样品检测峰的峰面积、峰起时间、峰止时间和保留时间的相对标准偏差(relative standard deviation,RSD)均〈2.0%。应用该方法对7批EV71灭活疫苗原液纯度进行检测,为95.3%-99.4%,均大于95%。结论:初步建立了可用于EV71灭活疫苗原液纯度测定的毛细管区带电泳方法,为该疫苗的质量研究、工艺过程控制及稳定性研究奠定了基础。 Objective: To establish a capillary zone electrophoresis( CZE) method for analyzing purity of enterovirus 71 inactivated vaccine. Methods: Based on the peak height,signal-to-noise ratio( S /N) and resolution,the running buffer,sample buffer,sample loading condition and length of uncoated silica capillary were optimized for establishing the CZE method. The separated peaks were identified by co-immunoprecipitation and high performance liquid chromatography( HPLC). The purity of enterovirus 71 inactivated vaccines was detected by the developed CZE method and determined by using the area normalization method. Results: A pH 8. 2 borate buffer containing 10 mmol·L^-1sodium dodecyl sulfate and 150 mmol·L^-1sodium chloride was used as running buffer,an uncoated silica capillary with length of 50 cm and diameter of 50 μ m was used as the chromatographic column,and sample loading time was 100 s. Under this condition,the capillary electrophoretogram was optimal; the peak andS /N were the highest and resolution was higher than 1. 5. The purity of EV71 inactivated vaccine was evaluated by CZE with 5 mmol·L^-1borate buffer solution as sample buffer. Two peaks were observed,peak 1 was identified as EV71 with a migration time of 6. 98 min and peak 2 as impurity proteins with a migration time of 8. 42 min by HPLC and co-immunoprecipitation assay. Relative standard deviations calculated from means of peak area,start time,stop time and migrate time were 2. 0%,respectively. The developed CZE was applied to detect purity of 7 batches of inactivated EV71 vaccine,and the result showed a purity of 95. 3% - 99. 4%. Conclusion: The CZE method used for purity detection of EV71 inactivated vaccine has been established,which is helpful for the quality control and stability study of the vaccine.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2370-2376,2405,共8页 Chinese Journal of New Drugs
基金 国家“重大新药创制”科技重大专项(2012ZX091319) 国家科技部863计划(2012AA02A401)
关键词 肠道病毒71型 灭活疫苗 毛细管区带电泳 纯度测定 免疫共沉淀 高效液相色谱 enterovirus type 71 inactivated vaccine capillary zone electrophoresis purity detection coimmunoprecipitation HPLC
  • 相关文献

参考文献22

  • 1吴星,张军楠,姚昕,毛群颖,高帆,王一平,梁争论.我国肠道病毒71型(EV71)疫苗株生物信息学分析[J].中国药事,2013,27(11):1180-1183. 被引量:3
  • 2ZHANG Y, TAN XJ, WANG HY,et al. An outbreak of hand, foot,and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China[ J]. J Clin Virol, 2009, 44 (4) :262 - 267.
  • 3YANG F, REN LL, XIONG ZH, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008 [ J]. J Clin Microbiol, 2009,47 (7) :2351 - 2352.
  • 4CHANG LY, KING CC, HSU KH, et al. Risk factors of entero- virus 71 infection and associated hand, foot, and mouth disease herpangina in children during an epidemic in Taiwan[ J]. Pediat- rics, 2002, 109(6) :e88 - e93.
  • 5MENG FY, LI JX, LI XL, et al. Tolerability and immunogenici- ty of an inactivated enterovirus 71 vaccine in Chinese healthy a- dults and children[ J ]. Hum Vaccin lmmunother, 2012, 8 (5) : 668 - 674.
  • 6ZHU FC, LANG ZL, LI XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and in- fants: a randomised, double-blind, placebo-controlled phase 2 clinical trial[J]. Lancet, 2013, 381 (9871) :1037 - 1045.
  • 7ZHU FC, MENG FY, LI XL, et al. Efficacy, safety, and immu- nology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [ J ]. Lancet, 2013, 381 (9882) :2024 - 2032.
  • 8Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks 2010[ S]. WHO techni- cal report series, No. 878, Annex 1. 2010.
  • 9OITA I, HALEWYCK H, PIETERS S, et al. Rational use of stacking principles for signal enhancement in capillary electro- phoretic separations of poliovirus samples [ J ] . J Pharm Biomed Anal, 2011, 55(1) :135 - 145.
  • 10BREADMORE MC. Recent advances in enhancing the sensitivity of electrophoresis and elcctrochromatography in capillary and mi- crochips[ J]. Electrophoresis ,2007, 28 ( 1 - 2 ) :254 - 281.

二级参考文献18

  • 1张志国,贾云虹,朱国辉.乳粉中核苷酸的检测方法[J].中国乳品工业,2004,32(11):42-44. 被引量:11
  • 2张海英.九州虫草5′-核苷酸的毛细管区带电泳分析[J].安徽农业科学,2007,35(18):5342-5343. 被引量:1
  • 3赵星洁,刘英华.毛细管电泳分离啤酒废酵母中4种5'-核苷酸[J].中国酿造,2007,26(8):68-71. 被引量:9
  • 4Brown BA, Oberste MS, Alexander JP Jr, et al. Molecu- lar epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998 [J]. J Virol, 1999, 73: 9969-9975.
  • 5Yoke-Fun C, AbuBakar S. Phylogenetic evidence for inter- typic recombination in the emergence of human enterovirus 71 subgenotypes[J]. BMC Microbiol, 2006, 6: 74-84.
  • 6Lin KH, Hwang KP, Ke genogroup in Taiwan from subgenogroup C4 of EV71 GM, et al. Evolution of EV71 1998 to 2005: an emerging of [J]. J Med Virol, 2006, 78(2): 254-262.
  • 7Palmenberg AC. Proteolytic processing of picornaviralpolyprotein [J]. AnnuRevMicrobiol, 1990, 44: 603-623.
  • 8Jeong EJ, Lee JH, Kim MS, et al. Molecular characteriza- tion of enteroviruses detected in Gyeong-Ju and Po-Hang provinces of Korea in 2003 [J]. Arch Virol, 2010, 155 (10): 1707-1712.
  • 9Gao F, Wang YP, Mao QY, et al. Enterovirus 71 viral capsid protein linear epitopes: identification and characteriza- tion [J]. VirolJ, 2012, 9 (1): 26-32.
  • 10Mao Q, Li N, Yu X, et al. Antigenicity, animal protec- tive effect and genetic characteristics of candidate vaccine strains of enterovirus 71 [J]. Arch Virol, 2012, 157 (1): 37-41.

共引文献6

同被引文献85

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部